ClinicalTrials.gg
CompletedNCT07266246Updated Sep 14, 2026

Effectiveness of Aluminum Foil vs White Linen Reflectors in Phototherapy for Neonatal Hyperbilirubinemia

An interventional study of reflective material in Premature, Phototherapy and Neonatal Intensive Care Unit, sponsored by Kubra Nur Kabakcı Sarıdağ. Completed at 1 site in Turkey (Türkiye). Open to participants aged 36 Weeks to 42 Weeks. Per ClinicalTrials.gov, last updated 2026-09-14.

Sponsored by Kubra Nur Kabakcı Sarıdağ · Not applicable, Interventional, and Supportive care

How we know

From the registry’s dates

  • Registered 8 months after the study started (first participant enrolled Dec 2024, registered Sep 2025).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
81
Allocation
Randomized
Ages
36 Weeks to 42 Weeks
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 247 studies in Premature Birth with a site in Turkey — 44 open to participants now, 49 under way, none of them phase 3. Premature Birth · Turkey.

Enrollment
58th of 197
81 · median 64
Started
2024
with 33 others
No phase
192 of 247
39 open now
Registered
209th of 247
by date

Among the 247 studies in Premature Birth with a site in Turkey, this one is the 58th largest by enrollment of the 197 interventional ones that give a count, is one of 34 that started in 2024, is one of 192 with no phase, and was the 209th registered.

Premature Birth

2,557 studies on the registry are indexed under Premature Birth; 504 are open to participants now.

Browse Premature Birth studies →

Open to participants now

44 of the 247 studies in Premature Birth with a site in Turkey are open now. Recruiting first, the newest first:

39 more — sign in →

All 44 open studies →

A study can be open while its sites in Turkey have not opened yet or have stopped. Only those recruiting at a site in Turkey →

Who these studies take

Of the 318 Premature Birth studies recruiting now, 88 (28%) set no upper age limit and 226 (71%) stop at 75 or younger; 243 take children under 18; 104 take healthy volunteers.

This study: 36 Weeks to 42 Weeks · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 247 studies in Premature Birth with a site in Turkey, or all of them as a file.
02

Study summary

Background: Indirect hyperbilirubinemia (IHB) is a common neonatal condition, affecting over 60% of term and 80% of preterm infants. Phototherapy is the most widely used, safe, and non-invasive treatment; however, scattering of phototherapy light decreases treatment efficacy, prolongs therapy duration, and increases the risk of side effects. Reflective materials have been suggested to enhance phototherapy effectiveness, yet studies comparing different reflector types remain limited.

Aim: This study aims to compare the effects of using reflective materials (white cloth or aluminum foil) during phototherapy on total serum bilirubin levels and phototherapy duration, in neonates with physiological IHB.

Methods: This single-center, single-blind, randomized controlled trial will be conducted at Ankara University Faculty of Medicine, Cebeci Neonatal Intensive Care Unit. A total of 81 neonates with gestational age 35-42 weeks and total serum bilirubin levels of 15-20 mg/dl will be randomly assigned into three groups: (1) phototherapy with white cloth reflectors, (2) phototherapy with aluminum foil reflectors, and (3) standard phototherapy (control). Data will be collected using an Introductory Information Form and Daily Follow-up Chart. Statistical analyses will include parametric and non-parametric tests based on distribution assumptions, with significance set at p\<0.05.

Expected Results: It is hypothesized that the use of reflective materials will result in faster reduction of total serum bilirubin and shorter phototherapy compared with standard phototherapy.

Conclusion: The study will provide evidence on the comparative effectiveness of two low-cost reflector materials in enhancing phototherapy outcomes, potentially offering a practical and efficient strategy for neonatal hyperbilirubinemia management.

03

Conditions studied

  • Premature
  • Phototherapy
  • Neonatal Intensive Care Unit
  • Neonatal Hyperbilirubinemia
  • Nursing
04

Who can participate

Ages eligible
36 Weeks to 42 Weeks
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Neonates with total serum levels between 15-20 mg/dL
  • Gestational age between 35-42 weeks
  • Birth weight between 2500-4000 g
  • APGAR score of 7-10 at the 1st and 5th minutes after birth
  • Fed with breast milk and/or formula
  • Written and verbal obtained from parents
  • Neonates who can be reached on the first day of phototherapy treatment

Exclusion criteria

Exclusion Criteria:

  • Neonates with Rh incompatibility
  • Neonates with ABO incompatibility
  • Neonates with any congenital anomaly
  • Neonates with asphyxia
  • Neonates receiving intensive (double) phototherapy
  • Neonates with glucose-6-phosphate dehydrogenase (G6PD) deficiency
  • Neonates with serum levels close to the exchange transfusion threshold
  • Neonates whose parents do not consent to participation in the study
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Supportive care
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Outcomes assessor)
Enrollment
81 participants (actual)

Study arms

  • Experimental
    Group using a white sheet as reflective material in conjunction with phototherapy

    The three sides of the incubator will be covered with a cardboard panel, cut to fit the incubator dimensions, lined with white linen cloth on the inner surface (length 88 cm, width 47 cm, height 34 cm).

    Other: reflective material

  • Experimental
    Group Using Aluminum Foil as Reflective Material in Combination with Phototherapy

    The incubators will be enclosed by a panel covered with aluminum foil on three sides (long side 88 cm, short side 47 cm, height 34 cm).

    Other: reflective material

  • No intervention
    Group Receiving Standard Single Phototherapy

    Infants will receive treatment in accordance with standard phototherapy practice.

Interventions

  • Otherreflective material

    When receiving phototherapy treatment in groups, reflective materials (aluminum foil-coated sheet or white sheet-covered sheet) were placed in the incubators.

06

What researchers measure

Primary outcomes

  1. Change in Total Serum Bilirubin Level

    The difference in total serum bilirubin concentration measured at baseline (before phototherapy), at the 4th hour, and at the last measurement during phototherapy, expressed in mg/dL.

    Time frame: At baseline (prior to phototherapy), 4 hours after initiation, and at the final assessment before discontinuation of phototherapy (up to 24 hours)

  2. Duration of Phototherapy

    Total duration of phototherapy received by each infant, recorded in hours.

    Time frame: Measured once at completion of phototherapy (up to 24 hours after initiation)

07

Study locations

1 site
  • Ankara Bilkent City Hospital
    Ankara, Turkey (Türkiye)
08

References and documents

Individual participant data

Plan to share: No — Individual participant data will not be shared.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Dec 2024 to primary completion in Jun 2025, 5 months.

Of 746 non-industry interventional studies with no phase under Premature Birth, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 47. This study's 5 months is below that.

Counting every sponsor, half of 764 studies reached it within 24 months; a quarter within 12 and three quarters within 47.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 23, 2025
First posted
Dec 5, 2025
StartActual
Dec 30, 2024
Primary completionActual
Jun 2, 2025
CompletionActual
Dec 1, 2025
Last update
Sep 14, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 14, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07266246
Lead sponsor
Kubra Nur Kabakcı Sarıdağ
Responsible party
Kubra Nur Kabakcı Sarıdağ (research assistant, Baskent University) — Sponsor-investigator
First posted
Dec 5, 2025
Start date
Dec 30, 2024
Primary completion
Jun 2, 2025
Completion
Dec 1, 2025
Last update
Sep 14, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion